Testing HCW9302 in adults with alopecia areata, an autoimmune hair loss condition
Tests HCW9302, an IL-2 fusion protein, in adults with alopecia areata.
Key facts
- Who runs it
- HCW Biologics
- Where
- Columbus, Indianapolis, and Tampa, United StatesSee the 3 sites
- Trial code
- Registry title
- HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 16 Aug 2025
- Expected to end
- 15 Dec 2027
- Type of study
- Interventional
- Treatments tested
- HCW9302, an IL-2 fusion protein
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with alopecia areata, a condition where the immune system causes patchy hair loss. Everyone gets one injection under the skin of HCW9302.
- Age
- Women 18 to 70 years; men 18 to 60 years.
- Sex
- Women and men can join.
- Disease stage
- Alopecia areata diagnosed by a doctor, including the ophiasis, totalis or universalis forms. People with mainly the "diffuse" type (spread-out hair shedding) cannot join.
- Earlier treatment
- No earlier Aldesleukin or investigational IL-2 analog. No phototherapy, systemic immunosuppressants or immune-changing biologic drugs in the 3 months before screening. No B-cell depleting drugs (such as rituximab) in the 6 months before screening.
- Biomarker or test result
- Blood tests within 28 days of treatment start: neutrophils ≥ 1,500/μL, platelets ≥ 100,000/μL, hemoglobin ≥ 10 g/dL, and kidney and liver tests within set limits. Women who could become pregnant need a negative blood pregnancy test within 14 days of treatment start.
Main reasons for not taking part
- Pregnant or breastfeeding, or unwilling to use birth control
- Another form of hair loss
- History of diabetes, cancer (except treated basal or squamous cell skin cancer), or recent heart attack or stroke
- Positive test for HIV, hepatitis B or hepatitis C, or active tuberculosis
- Earlier organ transplant or transplant from a donor
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Adult women who are 18 to 70 years of age, or adult males who are 18 to 60 years of age at the time of informed consent
- Clinical diagnosis of Alopecia Areata (AA) (including ophiasis, totalis or universalis forms) at Screening
- Negative serum pregnancy test within 14 days of treatment start if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized)
- Female subjects of childbearing potential must adhere to using a highly effective medically accepted method of birth control (defined as those with failure less than 1%; see Appendix 2) prior to screening and agree to continue its use for at least 28 days after the last dose of HCW9302 or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use a barrier method of birth control and agree to continue its use for at least 28 days after the last dose of HCW9302
- Laboratory tests performed within 28 days of treatment start:; Absolute neutrophil count (AGC/ANC) ≥ 1,500/μL (≥1.5 × 109/L); Platelets ≥ 100,000/μL (≥ 100 × 109/L); Hemoglobin ≥ 10 g/dL (>100g/L); Calculated glomerular filtration rate (GFR)* >40 mL/min OR serum creatinine ≤ 1.5 × ULN; Total bilirubin ≤ 2.0 × ULN or ≤ 3.0 × ULN for subjects with Gilbert's syndrome; AST, ALT, ALP ≤ 2.0 × ULN
- Able and willing to comply with requested study visits and procedures
- Able and willing to provide written informed consent and HIPAA authorization
Who cannot take part
- Prior use of any of the following treatments: a. Aldesleukin b. Investigational IL-2 analog
- Concurrent use of oral or topical treatments targeting hair growth or hair restoration (including but not limited to finasteride, dutasteride, topical minoxidil or oral minoxidil) if discontinuation or dosage change is planned during the study period
- Prior use of phototherapy and any systemic immunosuppressant (systemic steroids, cyclosporin, methotrexate or any other immunosuppressive therapy) or immunomodulating biologic therapy (including but not limited to dupilumab, tralokinumab, lebrikizumab, nemolizumab, rocatinlimab, or daxdilimab, whether marketed or investigational) within 3 months prior to Screening
- Prior use of any B-cell depleting agents, whether marketed or investigational, including but not limited to rituximab, ocrelizumab, ofatumumab, or belimumab, within 6 months prior to Screening
- History of myocardial infarction, congestive heart failure, uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months prior to Screening
- Significant organ dysfunction that is unstable or inadequately treated within 6 months prior to Screening
- Currently receiving any chronic systemic (oral or intravenous) anti-infective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria)
- Herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months prior to Screening. Subjects with a history of frequent outbreaks of Herpes Simplex Virus (defined as 4 or more outbreaks a year)
- Major surgery within 3 months prior to Screening visit or has a major surgery planned during the study
- Active systemic infection requiring parenteral antibiotic/antiviral therapy. All prior infections must have resolved following optimal therapy
- Prior organ allograft or allogeneic transplantation
- Any ongoing toxicity from prior therapies that, in the judgment of the Investigator, may interfere with study treatment. All toxicities attributed to prior therapy must resolve to grade 1 or baseline before administration of the study treatment
- Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study
- History of diabetes mellitus, regardless of whether it is controlled or not
- History of cancer or lymphoproliferative disease, except for the following: adequately treated basal cell or squamous cell skin cancer without current evidence of disease
- Active tuberculosis (TB) (based on TB blood test or a TB skin test) or a history of inadequately treated TB
- Positive based on serological screening for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening
- Psychiatric illness/social situations that would limit compliance with study requirements
- Other skin conditions that would interfere with study assessments of AA
- Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study
- Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding
- Patient has primarily "diffuse" type AA (characterized by diffuse hair shedding)
- Presence of another form of alopecia
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- The Ohio State University -Wexner Medical CenterColumbus, United StatesContact: Alison Wandling, B.S. CCRCTaking people
- Dawes Fretzin Clinical Research GroupIndianapolis, United StatesContact: Kenneth Dawes, MDTaking people
- James A. Haley Veterans HospitalTampa, United StatesContact: Adam Zoble, MSTaking people
About the trial
What the trial wants to find out
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
The group in the trial
- Study of HCW9302, an IL-2 fusion protein, for alopecia areataTreatment being tested
Single dose subcutaneous injection of HCW9302.
Treatment: HCW9302, an IL-2 fusion protein
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1 Study of HCW9302, an IL-2 Fusion Protein, for Alopecia Areata
- Plain-language title
- Testing HCW9302 in adults with alopecia areata, an autoimmune hair loss conditionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07049328, who can take part
- Record updated
- 15 September 2026